In five patients treated to date, transfer of MCPyV-specific autologous TCR-transduced CD8+ T cells proved safe, and transduced T cells were detectable in the tumor lesions for over one month after treatment (Veatch et al. 2022c). This evidence concerns the gene CD8A and neoplasm.